The renin-angiotensin system plays a major role in the pathogenesis of atherosclerosis. Most known effects of angiotensin II are mediated via activation of the AT 1 -receptor, which is in turn influenced to a great degree by levels of expression of the AT 1 -receptor. AT 1 -receptor activation is not only involved in vasoconstriction, water and salt homoeostasis and control of other neurohumoral systems, but also induces reactive oxygen species production, cellular hypertrophy and hyperplasia and apoptosis. Expression of this G-proteincoupled receptor is regulated by multiple factors. Among other conditions, oestrogen deficiency and hypercholesterolaemia increase AT 1 -receptor expression. Experimental data suggest that this augments the actions of angiotensin II, contributes to endothelial dysfunction, increases vascular production of reactive oxygen species, and via these mechanisms Keywords: AT 1 -receptors; atherosclerosis; oxidised LDL; reactive oxygen species; renin-angiotensin system; vascular smooth muscle
ing vascular smooth muscle growth and guiding the ultimate thickness of the vascular wall. 8, 9 While interesting and important roles of the AT 2 -receptor continue to be defined, most of the known functions of angiotensin II are related to AT 1 -receptor activation. AT 1 -receptors belong to the sevenmembrane-domain superfamily of G-proteincoupled receptors and are expressed in vascular smooth muscle cells, heart, lung, brain, liver, kidney, and adrenal glands.
3 AT 1 -receptors are coupled to a variety of intracellular signalling molecules, including the phospholipases A 2 , C and D, adenylate cyclase, voltage-dependent Ca 2+ -channels, and to a variety of kinases involved in phosphorylation cascades. [2] [3] [4] Depending on the cell and organ type, stimulation of these signal transduction pathways leads to cellular contraction, hypertrophy, proliferation, and/or apoptosis. [2] [3] [4] 10, 11 During the past few years, it has become apparent that one of the most important consequences of AT 1 -receptor activation, particularly in the cardiovascular system, is the production and release of reactive oxygen species. 12, 13 Reactive oxygen species and AT 1 
receptors
Several enzyme systems reduce molecular oxygen, resulting in formation of a variety of reactive oxygen species, including superoxide (O 2 ؒ− ), hydroxyl radical (HO ؒ ), hypochlorous acid (HOCl), lipid radicals, and hydrogen peroxide (H 2 O 2 ). 14, 15 Reactive oxygen species probably play a critical role in the normal functioning of cells. For example, the normal growth of vascular smooth muscle cells seems to require reactive oxygen species. 16 An excessive production of reactive oxygen species, outstripping antioxidant defence systems, has been referred to as 'oxidant stress' and has been implicated in many pathophysiological conditions in the cardiovascular system, including cigarette smoking, hypercholesterolaemia, diabetes, hypertension, and heart failure. 17 There are several untoward events that occur as a consequence of oxidant stress. These include oxidative modifications of DNA, lipid oxidation, modification of proteins, and activation of redox-sensitive genes. 18 Redox-sensitive genes are important in cardiovascular disease because many of these, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1) are proinflammatory and play a critical role in the initiation and progression of atherosclerosis. [19] [20] [21] Another significant consequence of reactive oxygen species is modification of enzyme function. An excellent example of this is the activation of matrix metalloproteinases (MMPs). These enzymes play a key role in allowing any cell to grow or migrate and are crucial in both vascular and myocardial remodelling. [22] [23] [24] AT 1 -receptor activation leads to production of reactive oxygen species in the vessel wall, in part because the AT 1 -receptor is linked to activation of an NADH/NADPH oxidase in vascular cells. 25 This oxidase system, which has similarities to the neutrophil oxidase, is a major source of reactive oxygen species in endothelial cells, vascular smooth muscle cells, and adventitial fibroblasts. 26, 27 How the various subunits interact in vascular cells, and how they produce superoxide, is not well understood. It is clear, however, that the vascular NADPH oxidase is responsive to hormones, metabolic factors, and mechanical forces. 26, 28 Besides growth factors and cytokines, angiotensin II is a principal activator of NADPH oxidase expressed in vascular smooth muscle cells and fibroblasts. 25, 26, 29 Furthermore, angiotensin II induces a rapid translocation of the small GTPase rac1 to the cellular membrane, a prerequisite of NADPH oxidase activation. 30 Besides these rapid effects, angiotensin II exerts long-term alterations by enhancing the gene expression of rac1, p22phox, and NOX-1. [25] [26] [27] 30 The NADPH oxidase is probably not the only source of reactive oxygen species stimulated by angiotensin II. Recently, it has become apparent that endothelial nitric oxide synthase (eNOS) can produce large amounts of superoxide under certain pathophysiological conditions. 31, 32 One mechanism for this relates to oxidative destruction of tetrahydrobiopterin, which is a critical co-factor for Journal of Human Hypertension eNOS function. [33] [34] [35] In the absence of tetrahydrobiopterin, eNOS transfers electrons to molecular oxygen rather than to L-arginine, resulting in superoxide production. Recent studies have suggested that any condition that increases superoxide production (so called 'kindling radicals') in the endothelium may ultimately lead to production of a large amount of superoxide ('bonfire radicals') from uncoupled eNOS. 36 Numerous intracellular targets for hydrogen peroxide and other reactive oxygen species have been described, including the mitogen-activated protein kinase (MAPK) family, the cell survival kinase Akt, ras/rac, c-src, protein kinase C, and tyrosine phosphotases. Reactive oxygen species also modulate intracellular Ca 2+ levels, altering numerous early signalling events. Many of these events have also been show to be downstream of AT 1 -receptor activation and are known to be redox-sensitive signalling targets.
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AT 1 -receptors and atherogenesis
One of the important consequences of increased superoxide production in response to angiotensin II is inactivation of nitric oxide. 17 Generally, the endogenous superoxide dismutases and other scavengers of superoxide keep this reaction to a minimum, but when cellular levels of superoxide are increased, for example upon angiotensin IIstimulation, this reaction proceeds. 42 Loss of nitric oxide via this mechanism leads to endothelial dysfunction, one of the earliest steps in the atherosclerotic process. Numerous cell culture, animal model and clinical studies have supported the concept that AT 1 -receptor activation causes vascular superoxide release in vitro and in vivo, leading to impaired endothelium-dependent vasodilation. 25, 43 In concert with these findings, inhibition of AT 1 -receptor activation by AT 1 -receptor antagonists or angiotensin converting enzyme (ACE) inhibitors improves endothelial dysfunction. [44] [45] [46] Loss of nitric oxide and formation of peroxynitrite promote atherosclerosis at virtually all stages of the disease. 17 The earliest stages of atherosclerotic disease are associated with increased attraction and adhesion of monocytes to the endothelium. 5 Inflammatory molecules such as MCP-1, ICAM-1, and VCAM-1 are critically important in this process. Importantly, expression of these is redox-sensitive and inhibited by nitric oxide. [19] [20] [21] 47 Angiotensin II induces their production and secretion via generation of reactive oxygen species and suppression of nitric oxide ( Figure 1 ).
Another phase of the atherosclerotic process is fatty streak formation, which is characterised by increased oxidation of low-density lipoprotein (LDL), uptake of oxLDL by macrophages and foam cell formation, processes that are promoted by AT 1 -receptor activation. 5, 48, 49 Of note, it has recently been demonstrated that expression of a receptor for oxidised LDL known as the LOX receptor, is dramatically increased by AT 1 -receptor activation. 48 In addition, oxLDL uptake may be also enhanced via angiotensin II effects on the cellular proteoglycan content. 49 Plaque formation is propagated by migration and proliferation of vascular smooth muscle cells. Again, there is ample evidence suggesting that the oxidant stress induced by angiotensin II plays a major role in stimulating growth and migration of vascular smooth muscle cells. 5, 17 Finally, plaque rupture is the result of increased lipid deposition, inflammatory events, apoptosis, and accelerated matrix degradation within the preformed vascular lesion. 5 Besides the enhanced lipid deposition, AT 1 -receptor activation initiates inflammatory processes such as interleukin-6 production. 50 Vascular smooth muscle cell apoptosis, which seems to be a prelude to plaque rupture, is induced via angiotensin II and prevented by AT 1 -receptor blockade. 10, 11 In keeping with these observations, angiotensin II increases MMP activity, resulting in plaque degradation and ultimately rupture. 24 Interestingly, recent reports have suggested that angiotensin II modulates haematopoiesis within the bone marrow. Monocyte CD11b-expression is enhanced, ultimately impacting on monocyteendothelial interactions. 7 To date, it is not clear whether endothelial dysfunction during early atherogenesis resembles the pathological state of endothelial cells shortly before or during plaque rupture. Within this review, both syndromes are referred to as endothelial dysfunction.
To summarise the above, angiotensin II, via its actions on the AT 1 -receptor, promotes the atherosclerotic process at virtually all stages of the disease (Figure 2 ). These actions of angiotensin II are at least in part mediated by reactive oxygen species.
Regulation of the AT 1 -receptor
Despite intense investigation in the last decade, many questions concerning the aetiology of atherosclerosis remain unanswered. Hypercholesterolaemia and hypertension are clearly risk factors for the development of vascular lesions, although the precise molecular steps between elevated lipid or blood pressure levels and the development of atherosclerotic lesions are not completely defined. 5, 51 Hypertension is frequently associated with additional risk factors such as hypercholesterolaemia, oestrogen deficiency, or hyperinsulinaemia. This clustering of risk factors greatly enhances the probability of developing atherosclerosis. 52 Nevertheless, the cellular events responsible for the mutual appearance of several risk factors are poorly understood.
Alexander and colleagues discovered that the vasoconstriction caused by angiotensin II in resistance vessels was variable. 53 Further investigations revealed that AT 1 -receptor activation is subject to a negative feedback, in that increased levels of angiotensin II diminish, and decreased angiotensin II concentrations enhance, AT 1 -receptor activation. [54] [55] [56] [57] More recently, it has been shown that multiple agonists other than angiotensin II modulate AT 1 -receptor expression. This phenomenon, referred to as heterologous AT 1 -receptor regulation, is induced by various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), or fibroblast growth factor (FGF) all of which downregulate AT 1 -receptor expression. 58 Numerous other factors, including glucocorticoids, aldosterone, forskolin, TNF␣, cytokines, nitric oxide, insulin, LDL, oestrogen, progesterone, sodium, free radicals, IGF-1, and isoprenaline are known to influence AT 1 -receptor expression. Hypercholesterolaemia-associated AT 1 -receptor overexpression Hypercholesterolaemia, and in particular elevated LDL plasma concentrations, play a fundamental role in the pathogenesis of atherosclerosis, as shown by numerous epidemiological and interventional studies. 5, 51 Moreover, hypercholesterolaemia is frequently associated with hypertension, another potent cardiovascular risk factor. 52 Despite this large body of epidemiological evidence, the molecular events leading from hypercholesterolaemia to hypertension and atherosclerosis are only partially understood. Recent studies have provided insights into these interactions. For example, it has been shown that exposure of vascular smooth muscle cells to LDL markedly augments AT 1 -receptor mRNA and protein expression. 88 Subsequent studies have extended these observations to the in vivo situation. In rabbits with diet-induced atherosclerosis or heritable hyperlipidaemia, aortic AT 1 -receptor expression is increased by two-fold. 89, 90 This has functional significance, in that angiotensin IIinduced vasoconstriction is markedly increased in these animals. Interestingly, vascular superoxide production is also increased in hypercholesterolaemia, and this is associated with profound alteration of endothelium-dependent vasodilation. These abnormalities are normalised by blockade of the AT 1 -receptor, despite the fact that blood pressure and lipoprotein levels are not changed by this treatment. Most importantly, development of atherosclerotic lesions can be greatly inhibited by AT 1 -receptor antagonism. These findings strongly support the concept that hypercholesterolaemia increases AT 1 -receptor expression, and illustrate how this phenomenon can contribute to atherosclerosis. Subsequent work has provided evidence that hypercholesterolemia increases AT 1 -receptor expression in humans. 91 In hypercholesterolaemic subjects, angiotensin II infusion produced more than twice the increase in blood pressure, compared with normocholesterolaemic subjects. In keeping with this finding, the expression of AT 1 -receptors was increased by two to three-fold in hypercholesterolaemic subjects. Of profound importance, treatment with statins for a 4-week period normalised the pressor response to angiotensin II infusion and completely normalised AT 1 -receptor expression. These results have been confirmed in another study of hypercholesterolaemic individuals, 92 and provide a molecular link between hyperlipidaemia and hypertension. Further, these studies provide insights into Journal of Human Hypertension why lipid lowering may have antihypertensive effects.
These findings are likely to have important clinical implications in that they help to explain some of the molecular mechanisms leading to the development and progression of hypertension and atherosclerosis in hypercholesterolaemia. Furthermore, they demonstrate why statins, which primarily inhibit cholesterol biosynthesis, may have favourable effects on blood pressure regulation, and why AT 1 -receptor antagonists have a beneficial effect on the atherosclerotic process.
Importantly, other components of the renin-angiotensin system, such as ACE, are also up-regulated during atherosclerosis as well as during hypercholesterolaemia. 93 In this context, high abundance of angiotensin II has also been shown in atherosclerotic plaques. 50 Therefore, an enhanced production of angiotensin II would coincide with AT 1 -receptor up-regulation, leading to an increased efficacy of the renin-angiotensin system and its deleterious consequences. Of note, ACE and AT 1 -receptors are components of the local renin-angiotensin system in the vessel wall. Regulation of these is likely to be completely independent of the circulating system, which appears not to be regulated during atherosclerosis.
Perspectives
Atherosclerosis is clearly caused by both a genetic predisposition and a variety of exogenous risk factors. Whereas the epidemiological correlation
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Journal of Human Hypertension between risk factors and atherosclerosis has been established, the molecular events initiated by those risk factors that ultimately lead to atherosclerosis remain poorly understood. It is apparent from the data accumulated to date that one possible link between risk factors and the development of vascular disease is in fact AT 1 -receptor activation. AT 1 -receptor regulation is very likely to represent a molecular switch connecting hypercholesterolaemia, oestrogen deficiency, hyperinsulinaemia and other risk factors with hypertension ( Figure 3) . From this point of view, AT 1 -receptor overexpression is one potential molecular mechanism that links a variety of exogenous risk factors to cellular events in the vascular disease. Currently, it is not certain if increased activity of other local components of the renin-angiotensin system such as ACE and angiotensin II is concomitantly required, or whether AT 1 -receptor overexpression itself is sufficient to propagate vascular lesion formation.
AT 1 -receptor antagonists or ACE inhibitors normalise oxidative stress and endothelial dysfunction and reduce the progression of atherosclerosis. [44] [45] [46] ACE inhibitors are known to retard the progression of atherosclerosis and heart failure. [93] [94] [95] In men suffering from coronary heart disease, ACE inhibitors improve endothelial dysfunction and reduce mortality from cardiovascular causes. 96 Recent studies in hypertensive and atherosclerotic individuals showed that AT 1 -receptor antagonists improved Figure 3 Role of risk factor-AT 1 -receptor interaction for the pathogenesis of atherosclerosis. Risk factors such as hypercholesterolaemia, oestrogen deficiency, or hyperinsulinaemia may increase AT 1 -receptor expression. Increased AT 1 -receptor expression results in increased oxidative stress, accelerated growth of vascular smooth muscle cells, and enhanced vasoconstriction. Presumably, AT 1 -receptor over expression is accompanied by up-regulation of vascular ACE and potentially other local components of the renin-angiotensin system. These deleterious events contribute, in concert with other co-morbid conditions, to elevated blood pressure, endothelial dysfunction (monocyte adhesion, procoagulation, impaired vasodilation) and progression of the atherosclerotic process. endothelial dysfunction, suggesting that these drugs, like ACE inhibitors, benefit vascular function. 46 However, large-scale trials are needed to confirm the efficacy of AT 1 -receptor antagonists with respect to reduction of morbidity and mortality in patients suffering from atherosclerosis.
In conclusion, AT 1 -receptor activation is one of the central pathophysiological events of atherosclerotic disease development and progression. Thus, inhibition of AT 1 -receptor activation should be considered essential in atheroprotective treatment regimens.
